Efficacy of Bidirectional Paclitaxel plus Capecitabine or Nilotinib for Peritoneal Carcinomatosis: A Single Institution Analysis of Two Phase II Clinical Trials
Bidirectional paclitaxel-based chemotherapy plus capecitabine may delay progression of gastric adenocarcinoma with peritoneal-only metastasis. Bidirectional paclitaxel-based chemotherapy plus nilotinib was associated with mostly stable peritoneal disease in this small, heterogenous cohort. Bidirectional paclitaxel combinations are feasible and may have a role in therapy for disease stabilization in individuals with peritoneal carcinomatosis.
Authors
- Stacy Joyce (ORCID: https://orcid.org/0009-0000-7318-841X)
- Christine Alewine (ORCID: https://orcid.org/0000-0003-1661-0957)
- Cassidy Bowden (ORCID: https://orcid.org/0000-0002-6746-6142)
- Andre Luiz De Souza (ORCID: https://orcid.org/0000-0001-6742-9774)
- Alice P. Chen (ORCID: https://orcid.org/0000-0002-1426-853X)
- Molly Sullivan
- Yvonne Mallory
- Shruthi R. Perati
- Jibran Ahmed (ORCID: https://orcid.org/0000-0002-3412-7689)
- Audra Satterwhite
- Andrew M. Blakely (ORCID: https://orcid.org/0000-0002-5013-3851)
- Sarah J. Shin (ORCID: https://orcid.org/0009-0008-8946-5918)
- Jonathan M. Hernandez
- J M Davis
- Nancy Moore
- Diane Ahn
- Stephanie Canady
- Silvia Figueiroa
- Monica Epstein
- Amber F. Gallanis
- John J. Lee
Institutions
- Dartmouth College (US)
- University of Maryland, Baltimore (US)
- National Institutes of Health (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- National Institutes of Health Clinical Center (US)
- Dartmouth Cancer Center
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2026-01-16
- DOI
- https://doi.org/10.1245/s10434-025-18967-2
- Citations
- 1
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 39.15
Funders
- U.S. Department of Health and Human Services
- AstraZeneca
- National Institutes of Health